There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biora Therapeutics (BIOR – Research Report), Bolt Biotherapeutics (BOLT – Research Report) and Immunovant (IMVT – Research Report) with bullish sentiments.
Biora Therapeutics (BIOR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics, with a price target of $50.00. The company’s shares closed last Monday at $2.44, close to its 52-week low of $1.76.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Biora Therapeutics is a Moderate Buy with an average price target of $50.00.
See the top stocks recommended by analysts >>
Bolt Biotherapeutics (BOLT)
H.C. Wainwright analyst Edward White reiterated a Buy rating on Bolt Biotherapeutics today and set a price target of $8.00. The company’s shares closed last Monday at $0.95, close to its 52-week low of $0.89.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Bolt Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.33, which is a 508.7% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $5.00 price target.
Immunovant (IMVT)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Immunovant, with a price target of $47.00. The company’s shares closed last Monday at $33.80.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunovant with a $42.69 average price target, representing a 26.0% upside. In a report issued on October 13, UBS also upgraded the stock to Buy with a $55.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIOR:
- Biora Therapeutics to Submit Updated IND Application for BT-600
- Biora Therapeutics presents data on BioJet systemic oral delivery platform
- Biora Therapeutics price target lowered to $50 from $65 at H.C. Wainwright
- Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
- Biora Therapeutics submits IND application to FDA for BT-600 program
